EyePoint (EYPT) Assets Average (2011 - 2026)
EyePoint (EYPT) posted Assets Average of $326.1 million for Q1 2026, up 5.93% sequentially from $307.8 million in Q4 2025, and down 16.49% YoY from $390.5 million in Q1 2025.
EyePoint (EYPT) Assets Average (2011 - 2026) Analysis & Trends
EyePoint has reported Assets Average for 16 years, with the latest figure at $326.1 million in Q1 2026.
- Quarterly Assets Average fell 16.49% year-over-year to $326.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $326.1 million (down 16.49% YoY) and the FY2025 annual result came in at $391.2 million, up 1.14% from the prior year.
- Assets Average advanced to $326.1 million in Q1 2026 per EYPT's latest filing, from $307.8 million in the prior quarter.
- Over five years, Assets Average peaked at $390.5 million in Q1 2025 and troughed at $165.1 million in Q2 2023.
- A 5-year average of $273.7 million and a median of $276.4 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2024: Assets Average sank 34.06% in 2023, then surged 104.34% in 2024.
- Over 5 years, Assets Average stood at $200.4 million in 2022, then increased by 28.53% to $257.6 million in 2023, then jumped by 39.62% to $359.7 million in 2024, then retreated by 14.41% to $307.8 million in 2025, then grew by 5.93% to $326.1 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $326.1 million, $307.8 million, and $276.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 258.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 258.20 Mn |
| Mar 31, 2026 | 326.11 Mn |
| Dec 31, 2025 | 307.85 Mn |
| Sep 30, 2025 | 276.42 Mn |
| Jun 30, 2025 | 331.86 Mn |
| Mar 31, 2025 | 390.51 Mn |
| Dec 31, 2024 | 359.69 Mn |
| Sep 30, 2024 | 312.58 Mn |
| Jun 30, 2024 | 326.75 Mn |
| Mar 31, 2024 | 342.22 Mn |
| Dec 31, 2023 | 257.61 Mn |
| Sep 30, 2023 | 167.85 Mn |
| Jun 30, 2023 | 165.12 Mn |
| Mar 31, 2023 | 167.47 Mn |
| Dec 31, 2022 | 200.42 Mn |
| Sep 30, 2022 | 226.96 Mn |
| Jun 30, 2022 | 238.99 Mn |
| Mar 31, 2022 | 253.96 Mn |
| Dec 31, 2021 | 215.81 Mn |
| Sep 30, 2021 | 173.54 Mn |